Features of Severe Liver Disease With Portal Hypertension in Patients With Cystic Fibrosis

Background & Aims Liver disease is the third leading cause of death in patients with cystic fibrosis (CF), but features of patients with CF, severe liver disease, and portal hypertension have not been characterized fully. Methods We performed a retrospective analysis of data from 561 patients wi...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:Clinical gastroenterology and hepatology 2016-08, Vol.14 (8), p.1207-1215.e3
Hauptverfasser: Stonebraker, Jaclyn R, Ooi, Chee Y, Pace, Rhonda G, Corvol, Harriet, Knowles, Michael R, Durie, Peter R, Ling, Simon C
Format: Artikel
Sprache:eng
Schlagworte:
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
container_end_page 1215.e3
container_issue 8
container_start_page 1207
container_title Clinical gastroenterology and hepatology
container_volume 14
creator Stonebraker, Jaclyn R
Ooi, Chee Y
Pace, Rhonda G
Corvol, Harriet
Knowles, Michael R
Durie, Peter R
Ling, Simon C
description Background & Aims Liver disease is the third leading cause of death in patients with cystic fibrosis (CF), but features of patients with CF, severe liver disease, and portal hypertension have not been characterized fully. Methods We performed a retrospective analysis of data from 561 patients with CF (63% male, 99% with pancreatic insufficiency), liver disease (hepatic parenchymal abnormalities consistent with cirrhosis, confirmed by imaging), and portal hypertension (esophageal varices, portosystemic collaterals, or splenomegaly), with no alternate causes of liver disease. All patients were enrolled in the Genetic Modifier Study of Severe CF Liver Disease at 76 international centers, from January 1999 through July 2013. Results Male patients were diagnosed with liver disease at a younger age than female patients (10 vs 11 y; P  = .01). Splenomegaly was observed in 99% of patients and varices in 71%. Levels of liver enzymes were near normal in most patients. Thrombocytopenia affected 70% of patients and was more severe in patients with varices (88 × 109 /L vs 145 × 109 /L; P < .0001). Ninety-one patients received liver transplants (16%), at a median age of 13.9 years. Compared with patients who did not receive liver transplants, patients who received liver transplants had lower platelet counts (78 × 109 /L vs 113 × 109 /L; P < .0001), higher international normalized ratios ( P < .0001), and lower levels of albumin ( P  = .0002). The aminotransferase to platelet ratio index (APRi) and fibrosis index based on 4 factor (FIB-4) values were higher than the diagnostic thresholds for CF liver disease in 96% and in 90% of patients, respectively. Patients who received liver transplants or who had varices had higher APRi and FIB-4 values than patients who did not. Conclusions In patients with CF, severe liver disease develops early in childhood (approximately 10 years of age), and is more common in boys than in girls. Patients with varices and those who receive liver transplants have more abnormal platelet counts and APRi and FIB-4 scores.
doi_str_mv 10.1016/j.cgh.2016.03.041
format Article
fullrecord <record><control><sourceid>proquest_pubme</sourceid><recordid>TN_cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_4955685</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><els_id>S1542356516300167</els_id><sourcerecordid>1805758416</sourcerecordid><originalsourceid>FETCH-LOGICAL-c540t-d917c739ef53e2bd62f2183a221ae4d854cdc6cc5cc0d5f2520a5969e8dcb1ab3</originalsourceid><addsrcrecordid>eNp9Uk2P0zAQjRCIXRZ-ABeUIxwabMfOh5BWWhVKkSqx0oI4cBi5k8nWJY27tlOp_4bfwi_DUcoK9sBpRvZ7bz7eJMlLzjLOePF2m-HtJhMxzVieMckfJedcSTErSy4fn_JcFeoseeb9ljFRy7p8mpyJkhWiZvI8-b4gHQZHPrVtekMHcpSuTAzpe-NJe0q_mbBJr60LukuXxz25QL03tk9N_-vntQ6G-uAn1Pzog8F0YdbOeuOfJ09a3Xl6cYoXydfFhy_z5Wz1-eOn-dVqhkqyMGtqXmKZ19SqnMS6KUQreJVrIbgm2VRKYoMFokJkjWqFEkyruqipanDN9Tq_SC4n3f2w3lGDsSGnO9g7s9PuCFYb-PenNxu4tQeQtVJFpaLAm0lg84C2vFrB-MbyStRclgcesa9PxZy9G8gH2BmP1HW6Jzt44BVTpaokLyKUT1CM6_CO2nttzmA0ELYQDYTRwFgCooGR8-rvWe4ZfxyLgHcTgOJGD4YceIwWIDXGEQZorPmv_OUDNnamN6i7H3Qkv7WD66NVwMELYHAzXtB4QHEaFmXK_DfUmMIs</addsrcrecordid><sourcetype>Open Access Repository</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>1805758416</pqid></control><display><type>article</type><title>Features of Severe Liver Disease With Portal Hypertension in Patients With Cystic Fibrosis</title><source>MEDLINE</source><source>ScienceDirect Journals (5 years ago - present)</source><creator>Stonebraker, Jaclyn R ; Ooi, Chee Y ; Pace, Rhonda G ; Corvol, Harriet ; Knowles, Michael R ; Durie, Peter R ; Ling, Simon C</creator><creatorcontrib>Stonebraker, Jaclyn R ; Ooi, Chee Y ; Pace, Rhonda G ; Corvol, Harriet ; Knowles, Michael R ; Durie, Peter R ; Ling, Simon C</creatorcontrib><description>Background &amp; Aims Liver disease is the third leading cause of death in patients with cystic fibrosis (CF), but features of patients with CF, severe liver disease, and portal hypertension have not been characterized fully. Methods We performed a retrospective analysis of data from 561 patients with CF (63% male, 99% with pancreatic insufficiency), liver disease (hepatic parenchymal abnormalities consistent with cirrhosis, confirmed by imaging), and portal hypertension (esophageal varices, portosystemic collaterals, or splenomegaly), with no alternate causes of liver disease. All patients were enrolled in the Genetic Modifier Study of Severe CF Liver Disease at 76 international centers, from January 1999 through July 2013. Results Male patients were diagnosed with liver disease at a younger age than female patients (10 vs 11 y; P  = .01). Splenomegaly was observed in 99% of patients and varices in 71%. Levels of liver enzymes were near normal in most patients. Thrombocytopenia affected 70% of patients and was more severe in patients with varices (88 × 109 /L vs 145 × 109 /L; P &lt; .0001). Ninety-one patients received liver transplants (16%), at a median age of 13.9 years. Compared with patients who did not receive liver transplants, patients who received liver transplants had lower platelet counts (78 × 109 /L vs 113 × 109 /L; P &lt; .0001), higher international normalized ratios ( P &lt; .0001), and lower levels of albumin ( P  = .0002). The aminotransferase to platelet ratio index (APRi) and fibrosis index based on 4 factor (FIB-4) values were higher than the diagnostic thresholds for CF liver disease in 96% and in 90% of patients, respectively. Patients who received liver transplants or who had varices had higher APRi and FIB-4 values than patients who did not. Conclusions In patients with CF, severe liver disease develops early in childhood (approximately 10 years of age), and is more common in boys than in girls. Patients with varices and those who receive liver transplants have more abnormal platelet counts and APRi and FIB-4 scores.</description><identifier>ISSN: 1542-3565</identifier><identifier>EISSN: 1542-7714</identifier><identifier>DOI: 10.1016/j.cgh.2016.03.041</identifier><identifier>PMID: 27062904</identifier><language>eng</language><publisher>United States: Elsevier Inc</publisher><subject>Adolescent ; Adult ; ALT ; CFLD ; Child ; Child, Preschool ; Cystic Fibrosis - complications ; Female ; Gastroenterology and Hepatology ; Humans ; Hypertension, Portal - epidemiology ; Hypertension, Portal - pathology ; INR ; Life Sciences ; Liver Diseases - complications ; Liver Diseases - epidemiology ; Liver Diseases - pathology ; Male ; Middle Aged ; Phenotype ; Portal Pressure ; Retrospective Studies ; Sex Factors ; Young Adult</subject><ispartof>Clinical gastroenterology and hepatology, 2016-08, Vol.14 (8), p.1207-1215.e3</ispartof><rights>AGA Institute</rights><rights>2016</rights><rights>Copyright © 2016. Published by Elsevier Inc.</rights><rights>Distributed under a Creative Commons Attribution 4.0 International License</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c540t-d917c739ef53e2bd62f2183a221ae4d854cdc6cc5cc0d5f2520a5969e8dcb1ab3</citedby><cites>FETCH-LOGICAL-c540t-d917c739ef53e2bd62f2183a221ae4d854cdc6cc5cc0d5f2520a5969e8dcb1ab3</cites><orcidid>0000-0002-7026-7523</orcidid></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktohtml>$$Uhttps://dx.doi.org/10.1016/j.cgh.2016.03.041$$EHTML$$P50$$Gelsevier$$H</linktohtml><link.rule.ids>230,314,780,784,885,3541,27915,27916,45986</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/27062904$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink><backlink>$$Uhttps://hal.science/hal-03829147$$DView record in HAL$$Hfree_for_read</backlink></links><search><creatorcontrib>Stonebraker, Jaclyn R</creatorcontrib><creatorcontrib>Ooi, Chee Y</creatorcontrib><creatorcontrib>Pace, Rhonda G</creatorcontrib><creatorcontrib>Corvol, Harriet</creatorcontrib><creatorcontrib>Knowles, Michael R</creatorcontrib><creatorcontrib>Durie, Peter R</creatorcontrib><creatorcontrib>Ling, Simon C</creatorcontrib><title>Features of Severe Liver Disease With Portal Hypertension in Patients With Cystic Fibrosis</title><title>Clinical gastroenterology and hepatology</title><addtitle>Clin Gastroenterol Hepatol</addtitle><description>Background &amp; Aims Liver disease is the third leading cause of death in patients with cystic fibrosis (CF), but features of patients with CF, severe liver disease, and portal hypertension have not been characterized fully. Methods We performed a retrospective analysis of data from 561 patients with CF (63% male, 99% with pancreatic insufficiency), liver disease (hepatic parenchymal abnormalities consistent with cirrhosis, confirmed by imaging), and portal hypertension (esophageal varices, portosystemic collaterals, or splenomegaly), with no alternate causes of liver disease. All patients were enrolled in the Genetic Modifier Study of Severe CF Liver Disease at 76 international centers, from January 1999 through July 2013. Results Male patients were diagnosed with liver disease at a younger age than female patients (10 vs 11 y; P  = .01). Splenomegaly was observed in 99% of patients and varices in 71%. Levels of liver enzymes were near normal in most patients. Thrombocytopenia affected 70% of patients and was more severe in patients with varices (88 × 109 /L vs 145 × 109 /L; P &lt; .0001). Ninety-one patients received liver transplants (16%), at a median age of 13.9 years. Compared with patients who did not receive liver transplants, patients who received liver transplants had lower platelet counts (78 × 109 /L vs 113 × 109 /L; P &lt; .0001), higher international normalized ratios ( P &lt; .0001), and lower levels of albumin ( P  = .0002). The aminotransferase to platelet ratio index (APRi) and fibrosis index based on 4 factor (FIB-4) values were higher than the diagnostic thresholds for CF liver disease in 96% and in 90% of patients, respectively. Patients who received liver transplants or who had varices had higher APRi and FIB-4 values than patients who did not. Conclusions In patients with CF, severe liver disease develops early in childhood (approximately 10 years of age), and is more common in boys than in girls. Patients with varices and those who receive liver transplants have more abnormal platelet counts and APRi and FIB-4 scores.</description><subject>Adolescent</subject><subject>Adult</subject><subject>ALT</subject><subject>CFLD</subject><subject>Child</subject><subject>Child, Preschool</subject><subject>Cystic Fibrosis - complications</subject><subject>Female</subject><subject>Gastroenterology and Hepatology</subject><subject>Humans</subject><subject>Hypertension, Portal - epidemiology</subject><subject>Hypertension, Portal - pathology</subject><subject>INR</subject><subject>Life Sciences</subject><subject>Liver Diseases - complications</subject><subject>Liver Diseases - epidemiology</subject><subject>Liver Diseases - pathology</subject><subject>Male</subject><subject>Middle Aged</subject><subject>Phenotype</subject><subject>Portal Pressure</subject><subject>Retrospective Studies</subject><subject>Sex Factors</subject><subject>Young Adult</subject><issn>1542-3565</issn><issn>1542-7714</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2016</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNp9Uk2P0zAQjRCIXRZ-ABeUIxwabMfOh5BWWhVKkSqx0oI4cBi5k8nWJY27tlOp_4bfwi_DUcoK9sBpRvZ7bz7eJMlLzjLOePF2m-HtJhMxzVieMckfJedcSTErSy4fn_JcFeoseeb9ljFRy7p8mpyJkhWiZvI8-b4gHQZHPrVtekMHcpSuTAzpe-NJe0q_mbBJr60LukuXxz25QL03tk9N_-vntQ6G-uAn1Pzog8F0YdbOeuOfJ09a3Xl6cYoXydfFhy_z5Wz1-eOn-dVqhkqyMGtqXmKZ19SqnMS6KUQreJVrIbgm2VRKYoMFokJkjWqFEkyruqipanDN9Tq_SC4n3f2w3lGDsSGnO9g7s9PuCFYb-PenNxu4tQeQtVJFpaLAm0lg84C2vFrB-MbyStRclgcesa9PxZy9G8gH2BmP1HW6Jzt44BVTpaokLyKUT1CM6_CO2nttzmA0ELYQDYTRwFgCooGR8-rvWe4ZfxyLgHcTgOJGD4YceIwWIDXGEQZorPmv_OUDNnamN6i7H3Qkv7WD66NVwMELYHAzXtB4QHEaFmXK_DfUmMIs</recordid><startdate>20160801</startdate><enddate>20160801</enddate><creator>Stonebraker, Jaclyn R</creator><creator>Ooi, Chee Y</creator><creator>Pace, Rhonda G</creator><creator>Corvol, Harriet</creator><creator>Knowles, Michael R</creator><creator>Durie, Peter R</creator><creator>Ling, Simon C</creator><general>Elsevier Inc</general><general>WB Saunders</general><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7X8</scope><scope>1XC</scope><scope>VOOES</scope><scope>5PM</scope><orcidid>https://orcid.org/0000-0002-7026-7523</orcidid></search><sort><creationdate>20160801</creationdate><title>Features of Severe Liver Disease With Portal Hypertension in Patients With Cystic Fibrosis</title><author>Stonebraker, Jaclyn R ; Ooi, Chee Y ; Pace, Rhonda G ; Corvol, Harriet ; Knowles, Michael R ; Durie, Peter R ; Ling, Simon C</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c540t-d917c739ef53e2bd62f2183a221ae4d854cdc6cc5cc0d5f2520a5969e8dcb1ab3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2016</creationdate><topic>Adolescent</topic><topic>Adult</topic><topic>ALT</topic><topic>CFLD</topic><topic>Child</topic><topic>Child, Preschool</topic><topic>Cystic Fibrosis - complications</topic><topic>Female</topic><topic>Gastroenterology and Hepatology</topic><topic>Humans</topic><topic>Hypertension, Portal - epidemiology</topic><topic>Hypertension, Portal - pathology</topic><topic>INR</topic><topic>Life Sciences</topic><topic>Liver Diseases - complications</topic><topic>Liver Diseases - epidemiology</topic><topic>Liver Diseases - pathology</topic><topic>Male</topic><topic>Middle Aged</topic><topic>Phenotype</topic><topic>Portal Pressure</topic><topic>Retrospective Studies</topic><topic>Sex Factors</topic><topic>Young Adult</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Stonebraker, Jaclyn R</creatorcontrib><creatorcontrib>Ooi, Chee Y</creatorcontrib><creatorcontrib>Pace, Rhonda G</creatorcontrib><creatorcontrib>Corvol, Harriet</creatorcontrib><creatorcontrib>Knowles, Michael R</creatorcontrib><creatorcontrib>Durie, Peter R</creatorcontrib><creatorcontrib>Ling, Simon C</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>MEDLINE - Academic</collection><collection>Hyper Article en Ligne (HAL)</collection><collection>Hyper Article en Ligne (HAL) (Open Access)</collection><collection>PubMed Central (Full Participant titles)</collection><jtitle>Clinical gastroenterology and hepatology</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Stonebraker, Jaclyn R</au><au>Ooi, Chee Y</au><au>Pace, Rhonda G</au><au>Corvol, Harriet</au><au>Knowles, Michael R</au><au>Durie, Peter R</au><au>Ling, Simon C</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Features of Severe Liver Disease With Portal Hypertension in Patients With Cystic Fibrosis</atitle><jtitle>Clinical gastroenterology and hepatology</jtitle><addtitle>Clin Gastroenterol Hepatol</addtitle><date>2016-08-01</date><risdate>2016</risdate><volume>14</volume><issue>8</issue><spage>1207</spage><epage>1215.e3</epage><pages>1207-1215.e3</pages><issn>1542-3565</issn><eissn>1542-7714</eissn><abstract>Background &amp; Aims Liver disease is the third leading cause of death in patients with cystic fibrosis (CF), but features of patients with CF, severe liver disease, and portal hypertension have not been characterized fully. Methods We performed a retrospective analysis of data from 561 patients with CF (63% male, 99% with pancreatic insufficiency), liver disease (hepatic parenchymal abnormalities consistent with cirrhosis, confirmed by imaging), and portal hypertension (esophageal varices, portosystemic collaterals, or splenomegaly), with no alternate causes of liver disease. All patients were enrolled in the Genetic Modifier Study of Severe CF Liver Disease at 76 international centers, from January 1999 through July 2013. Results Male patients were diagnosed with liver disease at a younger age than female patients (10 vs 11 y; P  = .01). Splenomegaly was observed in 99% of patients and varices in 71%. Levels of liver enzymes were near normal in most patients. Thrombocytopenia affected 70% of patients and was more severe in patients with varices (88 × 109 /L vs 145 × 109 /L; P &lt; .0001). Ninety-one patients received liver transplants (16%), at a median age of 13.9 years. Compared with patients who did not receive liver transplants, patients who received liver transplants had lower platelet counts (78 × 109 /L vs 113 × 109 /L; P &lt; .0001), higher international normalized ratios ( P &lt; .0001), and lower levels of albumin ( P  = .0002). The aminotransferase to platelet ratio index (APRi) and fibrosis index based on 4 factor (FIB-4) values were higher than the diagnostic thresholds for CF liver disease in 96% and in 90% of patients, respectively. Patients who received liver transplants or who had varices had higher APRi and FIB-4 values than patients who did not. Conclusions In patients with CF, severe liver disease develops early in childhood (approximately 10 years of age), and is more common in boys than in girls. Patients with varices and those who receive liver transplants have more abnormal platelet counts and APRi and FIB-4 scores.</abstract><cop>United States</cop><pub>Elsevier Inc</pub><pmid>27062904</pmid><doi>10.1016/j.cgh.2016.03.041</doi><orcidid>https://orcid.org/0000-0002-7026-7523</orcidid><oa>free_for_read</oa></addata></record>
fulltext fulltext
identifier ISSN: 1542-3565
ispartof Clinical gastroenterology and hepatology, 2016-08, Vol.14 (8), p.1207-1215.e3
issn 1542-3565
1542-7714
language eng
recordid cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_4955685
source MEDLINE; ScienceDirect Journals (5 years ago - present)
subjects Adolescent
Adult
ALT
CFLD
Child
Child, Preschool
Cystic Fibrosis - complications
Female
Gastroenterology and Hepatology
Humans
Hypertension, Portal - epidemiology
Hypertension, Portal - pathology
INR
Life Sciences
Liver Diseases - complications
Liver Diseases - epidemiology
Liver Diseases - pathology
Male
Middle Aged
Phenotype
Portal Pressure
Retrospective Studies
Sex Factors
Young Adult
title Features of Severe Liver Disease With Portal Hypertension in Patients With Cystic Fibrosis
url https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-14T20%3A34%3A08IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_pubme&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Features%20of%20Severe%20Liver%20Disease%20With%20Portal%20Hypertension%20in%C2%A0Patients%20With%20Cystic%20Fibrosis&rft.jtitle=Clinical%20gastroenterology%20and%20hepatology&rft.au=Stonebraker,%20Jaclyn%20R&rft.date=2016-08-01&rft.volume=14&rft.issue=8&rft.spage=1207&rft.epage=1215.e3&rft.pages=1207-1215.e3&rft.issn=1542-3565&rft.eissn=1542-7714&rft_id=info:doi/10.1016/j.cgh.2016.03.041&rft_dat=%3Cproquest_pubme%3E1805758416%3C/proquest_pubme%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=1805758416&rft_id=info:pmid/27062904&rft_els_id=S1542356516300167&rfr_iscdi=true